



# EARNINGS RELEASE 1Q | 2026

06.may.2026

## Belo Horizonte, May 6, 2026

Rede Mater Dei de Saúde (“Mater Dei” or “Company”) (B3: MATD3) announces its results for the first quarter of 2026 (1Q26). Figures are presented on a consolidated basis in BRL million, unless otherwise indicated. Comparisons refer to the first quarter of 2025 (YoY comparisons) and the fourth quarter of 2025 (QoQ comparisons). Quarterly information follows Brazilian and International (IFRS) accounting rules and was audited by independent auditors.

## Consolidated Figures

Financial Indicators (BRL million)	1Q26	1Q25	Δ	4Q25	Δ
Operational Beds (period average)	1,168	1,166	0.2%	1,207	(3.2%)
Patient-days (period total)	82,575	77,813	+6.1%	83,142	(0.7%)
Occupancy Rate (period average)	78.6%	74.2%	+4.4pp	74.9%	+3.7pp
Day Patient Occupancy Rate (average)	84.3%	79.7%	+4.6pp	80.5%	+3.8pp
Average Ticket (BRL MM/Bed)	2.86	2.64	+8.4%	2.79	+2.2%
Net Revenue	575	499	+15.1%	562	+2.3%
Gross Profit	174	144	+21.0%	172	+1.3%
Adjusted EBITDA	130	97	+34.6%	127	+2.2%
EBITDA Margin	22.6%	19.3%	+3.3pp	22.6%	-
Net Profit/Loss	36	20	+79.8%	37	(2.4%)
Net Debt	800	781	+19	800	-
Net Debt (ex-buybacks, dividends)	705	781	-76	706	-1
Net Debt (ex-buybacks, dividends)/EBITDA LTM	1.4x	1.6x	(0.2x)	1.5x	(0.1x)

# Highlights

## Operational and Financial



### Consolidated

- ✓ Quarterly Net Revenue and Adjusted EBITDA record
- ✓ Highest quarterly average ticket in the Network, with an increase of 8.4% vs. 1Q25
- ✓ 6.1% growth in the number of patient days vs. 1Q25
- ✓ 4.6 pp increase in occupancy rate vs. 1Q25, reaching a record for the network
- ✓ Reduction of Net Debt by R\$76 million vs. 1Q25 when disregarding share buybacks and dividends in the period

### RMBH

- ✓ 15% growth in Net Revenue vs 1Q25
- ✓ Nova Lima with a 19% increase in Net Revenue vs 4Q25, with a 13% growth in oncology patients and surgical notices

### Salvador:

- ✓ Record Net Revenue, with 23% growth vs. 1Q25
- ✓ 56% increase in oncology patients and 5% increase in surgical notices vs. 4Q25

### Acquired:

- ✓ 12% growth in Net Revenue vs. 1Q25
- ✓ 83% increase in oncology patients and 8% increase surgical notices vs. 1Q25
- ✓ HSG with the highest quarterly Net Revenue in history



## Partnership with American Heart Association

The Mater Dei Health Network reaffirms its commitment to educational excellence and high clinical performance by consolidating its strategic partnership with the American Heart Association (AHA). Doctors, nurses, and students will be able to elevate their professional level with internationally certified training, combining the scientific rigor of the AHA with experienced instructors and the cutting-edge technological infrastructure of the Mater Dei Contorno and Santo Agostinho Hospitals in Belo Horizonte.

## Awards ceremony for ICUs in Uberlândia

The Intensive Care Units at Mater Dei Hospital in Uberlândia received double recognition with the Top Performer ICU and Efficient ICU seals, awarded by Epimed Solutions in partnership with the Brazilian Association of Intensive Care Medicine (AMIB).



## Fitch maintains AA+(bra) rating.



On April 17, 2026, the credit rating agency Fitch Ratings (“Fitch”) reaffirmed the “AA+(bra)” rating of Hospital Mater Dei S.A. (Mater Dei) and its second issuance of unsecured debentures. The outlook for the corporate rating is Stable.

According to the Fitch report: “Mater Dei’s rating reflects the resilience of its operating cash generation in a still challenging environment and the solid long-term demand fundamentals of the hospital sector. The rating also incorporates the expectation of gradual maturation of the company’s hospital assets and the advancement of its operational strategy, which should support the expansion of cash generation and the maintenance of adequate profitability over the rating horizon.”


# Revenue

## Volume

Gross revenue is primarily composed of healthcare services provided, such as hospitalizations, surgeries, oncology, medical consultations, and exams, whether through health insurance operators, self-management plans, government entities, or private patients (out-of-pocket).


The first quarter of 2026 showed an average of 1,168 operational beds, stable compared to 1Q25. Compared to 4Q25, there was a reduction of 39 beds, resulting from the Company's strategy of operating with a higher occupancy rate, in addition to the historical seasonality of the first quarter, marked by holidays and Carnival. The quarterly occupancy rate reached 84.3%, 3.8 p.p. higher than 4Q25 and 4.6 p.p. higher than the same quarter of the previous year, reinforcing the established strategy.

**Evolution of average operational beds and occupancy rate<sup>1</sup>**



Compared to 4Q25, the patient-day volume registered a slight decrease of 0.7%, coupled with a 3% decrease in the average number of operational beds, aligned with the Company's strategy of operating with a higher occupancy rate to achieve operational efficiency. Compared to 1Q25, there was a significant growth of 6.1% in the patient-day volume, with stability in the number of beds.


**Number of Patient-days and Average Ticket (BRL/patient-day)**



# Revenue

## Consolidated Ticket and Figures

The consolidated average ticket price in the first quarter of 2026 increased by 8.4% and 2.2% compared to 1Q25 and 4Q25, respectively, reaching R\$2.86 million per bed used. The year-on-year growth is due to a better mix of specialties, procedures, and health insurance plans, with an increase in surgical notifications, oncology patients, and off-bed revenue; the change in the weighting of our hospitals' composition, with the ramp-up of Nova Lima and Salvador; and negotiations of annual adjustments with payers. Compared to 4Q25, the growth is due to a better mix of specialties, procedures, and hospitals.



In the first quarter of 2026, gross revenue totaled R\$ 644.3 million, an increase of 15.0% compared to the first quarter of the previous year and 1.5% above the gross revenue presented in the last quarter, highlighting the Company's momentum.

Gross revenue is mainly reduced by: (i) provision for disallowed claims; (ii) federal and municipal taxes levied on revenue and (iii) canceled invoices.

BRL million	Consolidated				
	1Q26	1Q25	Δ 1Q25	4Q25	Δ 4Q25
Providers	597.3	517.3	15.5%	589.9	1.3%
Private Patients	37.0	33.9	9.2%	35.8	3.3%
Other Revenues	10.1	9.2	9.2%	8.8	14.0%
<b>Gross Revenue</b>	<b>644.3</b>	<b>560.4</b>	<b>15.0%</b>	<b>634.5</b>	<b>1.5%</b>
Claim Denials	(28.0)	(24.3)	15.2%	(27.6)	1.3%
Taxes and Deductions	(41.4)	(36.7)	12.6%	(44.6)	(7.2%)
<b>Net Revenue</b>	<b>575.0</b>	<b>499.3</b>	<b>15.1%</b>	<b>562.3</b>	<b>2.3%</b>

# Costs

## Cost of Services Provided

The cost of services provided consists mainly of materials and medications, personnel, medical service provision, depreciation and amortization, and maintenance and repairs.

In 1Q26, the cost of services rendered totaled R\$ 401 million, representing 69.8% of net revenue, a decrease of 1.4 p.p. compared to 1Q25. These reductions are explained by the dilution of costs with increased revenue, mainly in the personnel line; by the Company's strategy of operating with a higher occupancy rate; and by adjustments to the workforce. When comparing 1Q26 with 4Q25, the cost-to-net-revenue ratio increased by 0.3 percentage points, mainly due to higher expenses on materials and medications.

In this sense, the reported Gross Profit was R\$ 173.9 million, while the gross margin reached 30.2%, since the effects on the costs of services rendered affect the margin in the same proportion.

BRL million	Consolidated				
	1Q26	1Q25	Δ 1Q25	4Q25	Δ 4Q25
Materials and medications	(155.7)	(129.8)	20.0%	(148.3)	5.0%
<i>% of net revenue</i>	27.1%	26.0%	1.1pp	26.4%	0.7pp
Personnel	(113.9)	(104.2)	9.3%	(109.8)	3.7%
<i>% of net revenue</i>	19.8%	20.9%	(1.1pp)	19.5%	0.3pp
Medical service provision	(60.6)	(55.1)	10.1%	(59.4)	2.0%
<i>% of net revenue</i>	10.5%	11.0%	(0.5pp)	10.6%	(0.1pp)
maintenance and conservation	(24.2)	(21.5)	12.2%	(24.9)	(2.9%)
<i>% of net revenue</i>	4.2%	4.3%	(0.1pp)	4.4%	(0.2pp)
Depreciation and amortization	(21.1)	(22.0)	-4.2%	(23.4)	(9.9%)
<i>% of net revenue</i>	3.7%	4.4%	(0.7pp)	4.2%	(0.5pp)
Other costs	(25.6)	(22.9)	11.6%	(24.8)	3.2%
<i>% of net revenue</i>	4.5%	4.6%	(0.1pp)	4.4%	0.1pp
<b>Cost of services provided</b>	<b>(401.0)</b>	<b>(355.5)</b>	<b>12.8%</b>	<b>(390.6)</b>	<b>2.7%</b>
<i>% of net revenue</i>	<b>69.8%</b>	<b>71.2%</b>	<b>(1.4pp)</b>	<b>69.5%</b>	<b>0.3pp</b>
<b>Gross Profit</b>	<b>173.9</b>	<b>143.8</b>	<b>21.0%</b>	<b>171.7</b>	<b>1.3%</b>
<i>% Gross Margin</i>	<b>30.2%</b>	<b>28.8%</b>	<b>1.5pp</b>	<b>30.5%</b>	<b>(0.3pp)</b>

# Expenses

## General, Administratives and Others

General and administrative expenses consist mainly of personnel expenses, depreciation and amortization, and other expenses inherent to back-office activities.

In 1Q26, general and administrative expenses reached 12.5% of net revenue for the period, stable compared to 4Q25 and 1.0 p.p. lower than 1Q25. This reduction is due to lower personnel expenses resulting from a readjustment of administrative positions and consequent dilution by revenue growth. Regarding net operating expenses, which mainly include provisions/reversals for legal claims, provisions for doubtful accounts, and equity method accounting, there was an increase of 0.6 p.p. compared to 4Q25, mainly due to a tax credit of R\$2.7 million at Santo Agostinho in the fourth quarter, without the same effect in the current quarter. Compared to 1Q25, there was a reduction due to lower contingency provisions.


BRL million	Consolidated				
	1Q26	1Q25	Δ 1Q25	4Q25	Δ 4Q25
Personnel	(43.1)	(43.4)	-0.7%	(42.0)	2.6%
<i>% of net revenue</i>	7.5%	8.7%	(1.2pp)	7.5%	-
Depreciation and amortization	(7.8)	(5.2)	48.6%	(5.5)	42.3%
<i>% of net revenue</i>	1.4%	1.0%	0.4pp	1.0%	0.4pp
Thid-party Services	(15.1)	(14.0)	8.4%	(16.4)	(7.6%)
<i>% of net revenue</i>	2.6%	2.8%	(0.2pp)	2.9%	(0.3pp)
Other Expenses	(5.7)	(4.6)	23.9%	(6.7)	(14.7%)
<i>% of net revenue</i>	1.0%	0.9%	0.1pp	1.2%	(0.2pp)
<b>General and Adm. Expenses</b>	<b>(71.7)</b>	<b>(67.2)</b>	<b>6.7%</b>	<b>(70.6)</b>	<b>1.6%</b>
<i>% of net revenue</i>	<b>12.5%</b>	<b>13.5%</b>	<b>(1.0pp)</b>	<b>12.6%</b>	<b>(0.1pp)</b>
Other rev./exp. Operational	(6.7)	(7.2)	-7.3%	(2.8)	139.8%
<i>% of net revenue</i>	1.2%	1.4%	(0.2pp)	0.5%	0.7pp
<b>Net operating expenses</b>	<b>(78.4)</b>	<b>(74.5)</b>	<b>5.3%</b>	<b>(73.4)</b>	<b>6.9%</b>
<i>% of net revenue</i>	<b>13.6%</b>	<b>14.9%</b>	<b>(1.3pp)</b>	<b>13.0%</b>	<b>0.6pp</b>

# EBIT and EBITDA

## Operational Result

Adjusted EBITDA for the quarter reached R\$130.0 million, a 2.2% increase compared to 4Q25 and a significant 34.6% growth compared to 1Q25. The adjusted EBITDA margin reached 22.6%, stable compared to 4Q25 and 3.3 p.p. higher compared to 1Q25. This increase is explained by three main factors: (i) increased revenue due to higher average ticket prices, volumes, and unit ramp-up, diluting costs/expenses and generating higher margins; (ii) review of personnel lines through the readjustment of staff and administrative positions; and (iii) increased occupancy rate aimed at greater operational efficiency. To present the most accurate operational result of what actually occurred in 1Q26, an adjustment of R\$ 5.6 million was made to EBITDA related to the provision for supplementary profit-sharing arising from the 2025 results, which impacted personnel cost and expense lines in the current quarter.

BRL millions	Consolidated				
	1Q26	1Q25	Δ 1Q25	4Q25	Δ 4Q25
<b>Gross Revenue</b>	644.3	560.4	15.0%	634.5	1.5%
Taxes, deductions and claim denials	(69.4)	(61.0)	13.6%	(72.2)	(3.9%)
<b>Net Revenue</b>	575.0	499.3	15.1%	562.3	2.3%
Costs of provided services	(401.0)	(355.5)	12.8%	(390.6)	2.7%
Net operational exp.	(78.4)	(74.5)	5.3%	(73.4)	6.9%
Asset Impairment	-	-	-	-	-
<b>EBIT</b>	95.5	69.3	37.7%	98.3	(2.9%)
<i>% of net revenue</i>	16.6%	13.9%	2.7pp	17.5%	(0.9pp)
Depreciation and Amort.	28.9	27.3	5.9%	28.9	-
<b>EBITDA</b>	124.4	96.6	28.8%	127.2	(2.2%)
<i>% of net revenue</i>	21.6%	19.3%	2.3pp	22.6%	(1.0pp)
Supplementary Provision for PS	5.6	-	-	-	-
<b>Adjusted EBITDA</b>	130.0	96.6	34.6%	127.2	2.2%
<i>% of net revenue</i>	22.6%	19.3%	3.3pp	22.6%	-



# Net Financial Result

## Financial Revenue and Expense

In the quarter, net financial income improved by 2.6% compared to 4Q25 due to lower interest expenses resulting from a reduction in average debt during the period, in addition to the SWAP variation in the "Other" line. These effects were partially offset by a reduction in financial income resulting from lower average cash flow during the period.


Compared to 1Q25, the variation in financial expenses is explained by higher lease interest expenses resulting from a higher average Selic rate and the SWAP variation in the "Other" line.

BRL millions	Consolidated				
	1Q26	1Q25	Δ 1Q25	4Q25	Δ 4Q25
<b>Financial Revenue</b>	<b>25.8</b>	<b>26.5</b>	<b>(2.8%)</b>	<b>29.0</b>	<b>(11.0%)</b>
<b>Financial Expenses</b>	<b>(70.2)</b>	<b>(65.7)</b>	<b>6.8%</b>	<b>(74.6)</b>	<b>(5.9%)</b>
<i>Interest on loans, financing, installments, and acquisitions</i>	(43.8)	(43.6)	0.6%	(46.2)	(5.2%)
<i>Lease interest</i>	(19.9)	(18.7)	6.6%	(19.6)	1.3%
<i>Others</i>	(6.5)	(3.5)	85.9%	(8.7)	(25.8%)
<b>Net Financial Result</b>	<b>(44.4)</b>	<b>(39.1)</b>	<b>13.4%</b>	<b>(45.6)</b>	<b>(2.6%)</b>



# Net Profit

In the current quarter, adjusted net income reached R\$ 36.3 million, a 79.8% increase compared to 1Q25, while the net margin reached 6.3%, registering a 2.3 pp growth year-on-year. These improved net income results are explained by the same effects that resulted in EBITDA growth, as described previously. Compared to 4Q25, there was a slight reduction in net income of 2.4%, resulting from the variation in the Income Tax/Social Contribution on Net Profit line item. The effective Income Tax and Social Contribution on Net Profit rate was impacted by the effect of temporary differences in the goodwill of assets and liabilities identified in the business combination. The value of this effect in 4Q25 was positive at R\$ 2.4 million, while in this quarter it corresponded to a deferred provision of R\$ 1.7 million.



BRL millions	Consolidated				
	1Q26	1Q25	Δ 1Q25	4Q25	Δ 4Q25
EBIT	95.5	69.3	37.7%	98.3	(2.9%)
Net Financial Result	(44.4)	(39.1)	13.4%	(45.6)	(2.6%)
<b>EBT</b>	<b>51.1</b>	<b>30.2</b>	<b>69.4%</b>	<b>52.7</b>	<b>(3.1%)</b>
Income Tax and S.C.N.P	(18.5)	(10.0)	85.3%	(15.6)	19.1%
<b>Net Profit</b>	<b>32.6</b>	<b>20.2</b>	<b>61.5%</b>	<b>37.2</b>	<b>(12.4%)</b>
<i>% of net revenue</i>	<i>5.7%</i>	<i>4.0%</i>	<i>1.7pp</i>	<i>6.6%</i>	<i>(0.9pp)</i>
Supplementary Provision for PS	3.7	-	-	-	-
<b>Adjusted Net Profit</b>	<b>36.3</b>	<b>20.2</b>	<b>79.8%</b>	<b>37.2</b>	<b>(2.4%)</b>
<i>% of net revenue</i>	<i>6.3%</i>	<i>4.0%</i>	<i>2.3pp</i>	<i>6.6%</i>	<i>(0.3pp)</i>


# Debt

In 1Q26, the net debt balance totaled R\$ 800 million, stable compared to the end of 2025 and 2.5% higher compared to 1Q25, resulting from the advance payment of dividends of R\$ 50 million and the acquisition of the remaining stake in Hospital Santa Clara for R\$ 56 million, which occurred in the fourth quarter of 2025, in addition to the payment of an installment for the acquisition of the Goiânia Hospital of R\$ 24 million that occurred in 1Q26. The leverage ratio (net financial debt/EBITDA LTM) reached 1.6x, stable compared to 1Q25 and 0.1x lower compared to 4Q25, due to the higher EBITDA LTM.


Consolidated (BRL millions)	1Q26	1Q25	Δ 1Q25	4Q25	Δ 4Q25
Short-Term Debt	94	103	-8.5%	115	-18.1%
Long-Term Debt	1,290	1,348	-4.3%	1,310	-1.6%
<b>Gross Debt<sup>1</sup></b>	<b>1,384</b>	<b>1,451</b>	<b>-4.6%</b>	<b>1,425</b>	<b>-2.9%</b>
Cash, cash equivalents, and financial investments	584	670	-1.9%	625	-6.6%
<b>Net Debt</b>	<b>800</b>	<b>781</b>	<b>2.5%</b>	<b>800</b>	<b>0.0%</b>
EBITDA LTM <sup>1</sup>	493	488	1.0%	466	5.7%
<i>Net Debt / EBITDA LTM</i>	<i>1.6</i>	<i>1.6</i>	<i>0.0</i>	<i>1.7</i>	<i>-0.1</i>

1. In accordance with the covenant of the Company's debenture issuances

In order to show the evolution of the company's cash generation over the last few quarters, we have created a hypothetical debt variation exercise below, excluding shareholder remuneration lines (share buybacks and dividends – paid and received). Over the last 12 months, net debt would have decreased by R\$ 76 million, while the leverage ratio in 1Q26 would be 1.4x. Below is a graph showing net debt (R\$ million) and accumulated buybacks/dividends (R\$ million):



Mater Dei's weighted average debt repayment term is 5.16 years vs. 5.34 years reported in 4Q25. The cost of debt in 1Q26 was CDI - 0.79% p.a.




Excludes transaction costs.

# Cash Flow

In 1Q26, cash generated from operations totaled R\$ 143 million, with R\$ 56 million consumed by working capital (accounts receivable, suppliers, inventory, among others). To complete the net cash flow generated by operating activities, there was a payment of R\$ 70 million in loan/lease interest for the semi-annual obligations of the Debentures, and R\$ 17 million in income tax and social contribution.

Investment activities consumed R\$ 12 million, in line with the established CAPEX control strategy. In addition, there was a negative variation of R\$ 10 million in the other lines that make up the cash flow. Cash reached R\$ 609 million, disregarding share buybacks, dividend receipts, and the payment of an installment for the acquisition of the Goiânia Hospital, reducing by only R\$ 16 million in the period even with the semi-annual obligations of the Debentures, demonstrating our efforts to transform the Network's operational performance into cash.



\*Contains the effect of cash amortization of the lease.

# Appendix

## P&L

<i>(BRL thousand)</i>	1Q26	1Q25	4Q25
<b>Gross Revenue</b>	<b>644,322</b>	<b>560,355</b>	<b>634,515</b>
Healthcare Operator	597,269	517,268	589,868
Out-of-pocket patients	36,975	33,865	35,808
Other revenue	10,078	9,222	8,839
<b>Taxes and Deductions</b>	<b>(69,364)</b>	<b>(61,037)</b>	<b>(72,212)</b>
<b>Net Revenue</b>	<b>574,958</b>	<b>499,318</b>	<b>562,303</b>
<b>Costs of services provided</b>	<b>(401,037)</b>	<b>(355,530)</b>	<b>(390,619)</b>
Medical Supplies and drugs	(155,683)	(129,756)	(148,292)
Personnel	(113,881)	(104,189)	(109,775)
Medical services	(60,619)	(55,074)	(59,437)
Maintenance and conservation	(24,153)	(21,536)	(24,880)
Depreciation and amortization	(21,101)	(22,034)	(23,423)
Other costs	(25,600)	(22,941)	(24,812)
<b>Gross profit</b>	<b>173,921</b>	<b>143,788</b>	<b>171,684</b>
<b>General and administrative expenses</b>	<b>(71,733)</b>	<b>(67,234)</b>	<b>(70,575)</b>
Personnel	(43,099)	(43,422)	(42,018)
Depreciation and amortization	(7,775)	(5,232)	(5,462)
Third-party services	(15,145)	(13,969)	(16,398)
Other expenses	(5,714)	(4,611)	(6,697)
<b>Equity pickup</b>	<b>94</b>	<b>(1,228)</b>	<b>(83)</b>
<b>Other operating income (expenses)</b>	<b>(6,807)</b>	<b>(6,012)</b>	<b>(2,716)</b>
<b>Impairment of assets- CPC 31</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Earnings before financial income and expenses</b>	<b>95,475</b>	<b>69,314</b>	<b>98,310</b>
Financial revenue	25,788	26,543	28,974
Financial expenses	(70,169)	(65,683)	(74,551)
<b>Net financial result</b>	<b>(44,381)</b>	<b>(39,140)</b>	<b>(45,577)</b>
<b>Earnings before income tax and social contribution</b>	<b>51,094</b>	<b>30,174</b>	<b>52,733</b>
<b>Income Tax and Social Contribution</b>	<b>(18,528)</b>	<b>(10,001)</b>	<b>(15,563)</b>
<b>Net Income / (Loss)</b>	<b>32,566</b>	<b>20,173</b>	<b>37,170</b>
Deferred Income tax (goodwill)	3,703	-	-
Divestment of assets / Impairment of assets	<b>36,269</b>	<b>20,173</b>	<b>37,170</b>

<i>(BRL thousand)</i>	1Q26	1Q25	4Q25
<b>EBIT</b>	<b>95,475</b>	<b>69,314</b>	<b>98,310</b>
Depreciation and amortization	28,876	27,266	28,885
<b>EBITDA</b>	<b>124,351</b>	<b>96,580</b>	<b>127,195</b>
Nova Lima preoperational	5,610	-	-
Divestment of assets / Impairment of assets	<b>129,961</b>	<b>96,580</b>	<b>127,195</b>

# Appendix

## Balance Sheet

(BRL thousand)	31/03/2026	31/03/2025	31/12/2025
<b>Asset</b>			
<b>Current</b>			
Cash and Cash Equivalents	556,803	616,113	599,130
Financial Investments	27,168	54,300	26,328
Accounts receivable	768,819	688,276	717,064
Inventories	78,882	62,268	71,785
Derivatives	-	-	-
Construction Reimbursement	43,661	41,800	43,195
Construction assets to be deployed	-	-	-
Other current assets	40,072	56,098	36,591
Assets held for sale	-	-	-
<b>Total current assets</b>	<b>1,515,405</b>	<b>1,518,855</b>	<b>1,494,093</b>
<b>Non-current</b>			
Construction Reimbursement	251,050	282,150	259,168
Judicial deposits	61,392	53,456	60,666
Deferred taxes	233,511	225,364	234,266
Derivatives	-	-	-
Investments	10,978	12,393	11,506
Right of use	680,173	674,020	665,852
Fixed Assets	793,001	832,274	811,604
Intangible Assets	730,070	729,901	730,498
Other non-current assets	59,390	48,954	45,236
<b>Total non-current assets</b>	<b>2,819,565</b>	<b>2,858,512</b>	<b>2,818,796</b>
<b>Total Assets</b>	<b>4,334,970</b>	<b>4,377,367</b>	<b>4,312,889</b>
<b>Liabilities</b>			
<b>Current</b>			
Suppliers	146,935	137,031	148,566
Loans and financing	91,935	100,691	112,332
Derivatives	2,246	2,217	2,599
Leasing	80,641	69,306	78,371
Salaries & social security contribution	79,935	67,562	66,891
Taxes and contributions payable	43,997	27,702	38,519
Installment payment of taxes	153	3,941	338
Accounts payable of company acquisition	67,186	36,085	30,761
Redemption liability	2,383	61,414	2,383
Dividends payable	-	-	-
Other current liabilities	5,796	8,569	10,346
Liability held for sale	-	-	-
<b>Total current liabilities</b>	<b>521,207</b>	<b>514,518</b>	<b>491,106</b>
<b>Non-current</b>			
Loans and financing	1,273,060	1,329,427	1,290,122
Derivatives	17,038	19,028	20,361
Leasing	716,416	696,414	698,427
Redemption liability	-	-	-
Installment payment of taxes	508	648	508
Deferred taxes liabilities	75,530	77,548	74,362
Accounts payable of company acquisition	84,212	138,398	141,639
Provision for contingencies	126,935	107,139	110,241
Other non-current liabilities	8,364	9,230	8,549
<b>Total non-current liabilities</b>	<b>2,302,063</b>	<b>2,377,832</b>	<b>2,344,209</b>
<b>Equity Capital</b>			
Capital	1,301,019	1,301,019	1,301,019
Capital reserves	174,897	183,915	140,898
Income reserves	90,659	57,875	90,659
(-) Treasury stocks	(7,577)	(4,934)	(6,303)
Equity valuation adjustment	(60,219)	(83,235)	(61,785)
<b>Total equity attributable to the Company's shareholder</b>	<b>1,498,779</b>	<b>1,454,640</b>	<b>1,464,488</b>
Share of noncontrolling shareholders	12,921	30,377	13,086
<b>Total Shareholders' equity</b>	<b>1,511,700</b>	<b>1,485,017</b>	<b>1,477,574</b>
<b>Total Liabilities</b>	<b>4,334,970</b>	<b>4,377,367</b>	<b>4,312,889</b>

# Appendix

## Cash Flow

<i>(BRL thousand)</i>	31/03/2026	31/03/2025
<b>Cash flow from operating activities</b>		
Net profit for the period	32,566	20,173
<b>Adjustments to reconcile net income to cash from operations</b>		
Depreciation and amortization	28,876	27,266
Write-off of fixed and intangible assets	2,077	883
Establishment (reversal) of allowance for doubtful accounts	6,576	5,741
Establishment (reversal) of provision for disallowances	24,993	-10,065
Establishment (reversal) of provision and restatement for contingencies	2,277	1,835
Share-Based Payment provision	794	1,731
Equity pickup gains	(94)	1,228
Derivative Gains	3,110	66
Income from financial investments	(18,174)	(18,642)
Net financial expenses	58,106	57,141
Provision for income tax and social contribution - current & deferred	2,506	3,689
	<b>143,613</b>	<b>91,046</b>
<b>Variations in Operating Assets and Liabilities</b>		
Accounts Receivable	(84,097)	(22,517)
Inventories	(1,256)	(12,511)
Other Assets	(2,809)	(4,496)
Judicial Deposits	1,743	(1,363)
Suppliers	387	6,214
Salaries and social security contributions	13,044	11,383
Taxes and contributions payable	22,172	5,181
Tax installments	(198)	(1,848)
Other liabilities	(5,319)	649
	<b>(56,333)</b>	<b>(19,308)</b>
Income tax and social contributions paid	(16,694)	(3,731)
Interest paid	(70,023)	(16,170)
<b>Net cash generated by operating activities</b>	<b>563</b>	<b>51,837</b>
<b>Cash Flow of Investment activities</b>		
Acquisition of fixed assets	(8,695)	(10,197)
Acquisition of intangible assets	(2,896)	(2,773)
Developments with construction to be deployed	-	-
Investment acquisition	-	-
Controlled consolidation of initial cash	(19,828)	(20,972)
Disposal of investments	-	-
Cash from investment acquisition (disposal)	-	-
Financial investments made, net redemptions	17,334	17,077
<b>Net cash generated (used) in investment activities</b>	<b>(14,085)</b>	<b>(16,865)</b>
<b>Cash flow from financing activities</b>		
Loans and financing	-	-
Payments of loans and financing	(16,334)	(23,507)
Lease payments	(7,261)	(5,919)
Derivative settlement	(4,116)	(1,543)
Treasury stocks	(1,537)	(10,471)
Dividends paid	443	-
<b>Net cash provided by (used in) financing activities</b>	<b>(28,805)</b>	<b>(41,440)</b>
<b>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>(42,327)</b>	<b>(6,468)</b>
Cash and cash equivalents at the beginning of the period	599,130	622,581
Cash and cash equivalents at the end of the period	556,803	616,113
<b>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>(42,327)</b>	<b>(6,468)</b>

# Glossary and Other Information

**AoP:** Average of period

**LTM:** Last Twelve Months

**IFRS 16:** As of January 1st, 2019, all companies had to adapt to the new rules of IFRS 16, With this new standard, lessees now have to recognize the asset of rights over leased assets and the liability of future payments for medium or long-term leases, including operating leases, The biggest impact we had was on the real estate lease contracts of our operational and administrative units,

**EBITDA:** Earnings before Interest, Taxes, Depreciation and Amortization

**EBITDA Margin:** EBITDA divided by net revenue

**EBIT:** Earnings before Interest and Taxes

**CDI:** Interbank Deposit Certificate

**Occupancy rate:** Number of beds occupied by patients per day added up over a given period, divided by the number of beds that were operational each day added up during the same period

## About Rede Mater Dei de Saúde

Rede Mater Dei de Saúde is an integrated platform that provides hospital and cancer services, being a national reference in health and the largest private hospital network in Minas Gerais, The Company has more than 2,200 beds of capacity in its 9 units located in the metropolitan region of Belo Horizonte ("MRBH"), Salvador, Uberlândia, Goiânia and Feira de Santana,

Rede Mater Dei has a clinical expertise that is recognized by patients, medical community, healthcare operators, suppliers, and relevant sectors of the Brazilian Society, and focuses on innovation and medical pioneering,

## Relationship with independent auditors

In accordance with CVM Resolution CVM 162/22, we inform that our policy for hiring independent auditors considers the best governance principles, which reserve the auditor's independence, in accordance with internationally accepted criteria,

*For additional Investor Relations information, please access the website: <https://ri,materdei.com,br/en/> or e-mail [ri@materdei.com,br](mailto:ri@materdei.com,br)*

*This material contains summary information, which is not intended to be complete and should not be considered by shareholders or potential investors as an investment recommendation, Information about Mater Dei, its activities, economic and financial situation, and the risks inherent to its activities, as well as its financial statements, can be obtained on the world wide web, on the Mater Dei website (<https://ri,materdei.com,br/en/>)*



### **HUB BRASIL CENTRAL**

Mater Dei Goiânia  
Goiânia/GO

Mater Dei Santa Clara  
Uberlândia/MG

Mater Dei Santa Genoveva  
Uberlândia/MG

Mater Dei CDI  
Uberlândia/MG

### **SÃO PAULO**

Mater Dei São Paulo  
[em construção]

### **HUB BAHIA**

Mater Dei Salvador  
Salvador/BA

Mater Dei Emec  
Feira de Santana/BA

### **HUB RMBH**

Mater Dei Santo Agostinho  
Belo Horizonte/MG

Mater Dei Contorno  
Belo Horizonte/MG

Mater Dei Betim-Contagem  
Betim/MG

Mater Dei Nova Lima  
Nova Lima/MG